Phase I Study of Cellular Immunotherapy Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Patients With Recurrent/Refractory Malignant Glioma

Trial Profile

Phase I Study of Cellular Immunotherapy Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Patients With Recurrent/Refractory Malignant Glioma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs MB 101 (Primary)
  • Indications Glioblastoma; Glioma
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Nov 2017 Planned number of patients changed from 100 to 135.
    • 11 Oct 2017 According to a Mustang Bio media release, this trial has recieved a $12.8 million grant from the California Institute for Regenerative Medicine (CIRM). This grant will enable the expansion of this trial to continue to explore the most effective delivery methods of MB-101.
    • 22 Aug 2017 According to a Mustang Bio media release, the company expects to read-out data from this study in early 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top